Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients

Drug and Alcohol Review

Volumn 30, Issue 6, 2011, Pages 613-620

  Larance, Briony ^a   Degenhardt, Louisa ^a   O'Brien, Susannah ^a   Lintzeris, Nick ^b   Winstock, Adam ^c   Mattick, Richard P ^a   Bell, James ^d   Ali, Robert ^e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Buprenorphine; Diversion; Injection; Methadone; Opioid substitution treatment

Indexed keywords

BUPRENORPHINE; METHADONE; NALOXONE; NARCOTIC AGENT;

ARTICLE; AUSTRALIA; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION PROCESSING; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PERCEPTION; PHARMACIST; SELF REPORT;

ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; BUPRENORPHINE; DATA COLLECTION; HUMANS; MEDICATION ADHERENCE; METHADONE; NALOXONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PERCEPTION; PHARMACISTS; SELF REPORT;

EID: 80155183116     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2010.00274.x     Document Type: Article

References (36)

1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
2. Mattick RP, Degenhardt L. Methadone-related and heroin-related deaths among opiate users: methadone helps save lives. Addiction 2003;98:387-8.
3. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;(2):Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub3.
4. World Health Organisation/United Nations Office on Drugs and Crime/Joint United Nations Programme on HIV/AIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Geneva: World Health Organisation, 2004.
5. Winstock AR, Bell J. Clinical Guidelines: Assessing suitability for unsupervised medication doses in the treatment of opioid dependency. Sydney: The Royal Australasian College of Physicians, Adult Medicine Division, 2006.
6. Department of Health and Ageing. National pharmacotherapy policy for people dependent on opioids. Canberra: Commonwealth of Australia, 2007.
7. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8:171-83.
8. Larance B, Degenhardt L, Mattick RP, etal. The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2009.
9. Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. Int J Drug Policy 2006;17:192-202.
10. Fraser S, Valentine K, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales and Victoria: takeaways, diversion and other key issues. Sydney: National Centre for HIV Social Research, University of New South Wales, 2007.
11. Treloar C, Fraser S, Valentine K. Valuing methadone takeaway doses: the contribution of service-user perspectives to policy and practice. Drugs Edu Prev Policy 2007;14:61-74.
12. Edwards P, Roberts I, Clarke M, etal. Increasing response rates to postal questionnaires: systematic review. BMJ 2002;324:1183.
13. Edwards PJ, Roberts I, Clarke MJ, etal. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009;(3):Art. No.: MR000008. DOI: 10.1002/14651858.MR000008.pub4.
14. Australian Institute of Health and Welfare, ed. National Opioid Pharmacotherapy Statistics Annual Data collection: 2007 report. Canberra: Australian Institute of Health and Welfare, 2008.
15. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 2008;19:450-8.
16. Winstock AR, Lea T, Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009;28:269-78.
17. Robinson GM, Kemp R, Lee C, Cranston D. Patients in methadone maintenance treatment who inject methadone syrup: a preliminary study. Drug Alcohol Rev 2000;19:447-50.
18. Fountain J, Strang J, Gossop M, Farrell M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000;95:393-406.
19. Pelet A, Besson J, Pecoud A, Favrat B. Difficulties associated with outpatient management of drug abusers by general practitioners with and without methadone patients in Switzerland. BMC Fam Pract 2005;6:1-7.
20. Roche AM, Guray C, Saunders J. General practitioners' experiences of patients with drug and alcohol problems. Br J Addict 1991;86:263-75.
21. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev 2007;26:143-51.
22. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-81.
23. Winstock AR, Lea T, Jackson AP. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. J Addict Dis 2009;28:57-63.
24. Winstock A, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction 2010;105:335-42.
25. Roche AM, Hotham ED, Richmond RL. The general practitioner's role in AOD issues: overcoming individual, professional and systemic barriers. Drug Alcohol Rev 2002;21:223-30.
26. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80.
27. Julius RJ, Novitsky MAJ, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009;15:34-44.
28. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006;6:48.
29. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67:1114-23.
30. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy R. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviours: a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guidelines. J Pain 2009;10:131-46.
31. Webster LR, Webster RM. Predicting aberrant behaviours in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-42.
32. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviours are predictive of current substance use and mental health problems in primary care patients. Pain Med 2008;9:1098-106.
33. Passik SD, Kirsh KL. The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. Pain Med 2003;4:186-9.
34. Meghani SH, Wiedemer NL, Becker WC, Gracely EJ, Gallagher RM. Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med 2009;10:858-65.
35. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviours in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22:173-81.
36. Aitken C, Power R, Dwyer R. A very low response rate in an on-line survey of medical practitioners. 2008;32:288-9.